# Pharmacokinetics, Pharmacodynamics, Safety, and Preliminary Efficacy of Subcutaneous Injection of SHR-1905 in Adolescent Asthmatic Subjects - an Open-label, Single-dose Phase II Clinical Study

> **NCT06786455** · PHASE2 · COMPLETED · sponsor: **Guangdong Hengrui Pharmaceutical Co., Ltd** · enrollment: 9 (actual)

## Conditions studied

- Adolescent Asthma

## Interventions

- **DRUG:** SHR-1905 Injection

## Key facts

- **NCT ID:** NCT06786455
- **Lead sponsor:** Guangdong Hengrui Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-01-23
- **Primary completion:** 2025-12-03
- **Final completion:** 2025-12-03
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2025-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06786455

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06786455, "Pharmacokinetics, Pharmacodynamics, Safety, and Preliminary Efficacy of Subcutaneous Injection of SHR-1905 in Adolescent Asthmatic Subjects - an Open-label, Single-dose Phase II Clinical Study". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT06786455. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*